Medication for Opioid Use Disorder (MOUD)-Recording

Video Transcription

Video Summary

The session focused on Medicines for Opioid Use Disorder (MOUD) and the distinctions from Medication-Assisted Treatment (MAT). The discussion emphasized the importance of terminology to combat stigma and accurately describe treatments. Methadone and buprenorphine are key medications for opioid use disorder (OUD), with methadone being a full agonist and buprenorphine a partial agonist at opioid receptors. Methadone can be used with full opioid effect and helps alleviate withdrawal symptoms, but may cause some side effects like nodding out, which is a sign the medication is effective rather than causing euphoria. Buprenorphine, often combined with naloxone, is designed to minimize misuse by causing withdrawal if additional opioids are consumed.<br /><br />The instructors clarified misconceptions regarding the effectiveness of buprenorphine with fentanyl users, indicating that higher dosages or dosing adjustments ensure its efficacy. Access to buprenorphine has been simplified under recent legislation, making it accessible through primary care providers.<br /><br />The session also covered MAT for other addictions, emphasizing the use of medications like naltrexone and antabuse specific for alcohol use disorder, and nicotine replacements for tobacco. Methamphetamine lacks FDA-approved treatments, with contingency management as the primary approach.<br /><br />Stigma around MOUD and misconceptions were addressed, particularly the incorrect beliefs that these treatments perpetuate addiction or health issues, highlighting how stigma limits treatment access. Recommendations were made for discussing treatment options with clients, aiming to provide accurate information while recognizing the challenge of overcoming stigma and self-stigma.

Keywords

Medicines for Opioid Use Disorder

MOUD

Medication-Assisted Treatment

MAT

methadone

buprenorphine

opioid use disorder

OUD

stigma

naloxone

fentanyl

naltrexone

antabuse